PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Inosine treatment safely elevates urate levels in Parkinson's disease patients

Phase 2 trial supports further investigation of urate's ability to slow disease progression

2013-12-27
(Press-News.org) Contact information: Mike Morrison
mdmorrison@partners.org
617-724-6425
Massachusetts General Hospital
Inosine treatment safely elevates urate levels in Parkinson's disease patients Phase 2 trial supports further investigation of urate's ability to slow disease progression A clinical trial assessing the potential of the nutritional supplement inosine to treat Parkinson disease has found that the studied dosages successfully raised participants' levels of the antioxidant urate without producing serious side effects. Results of the two-year phase 2 trial – conducted by a consortium led by investigators at Massachusetts General Hospital (MGH), Harvard School of Public Health, and the University of Rochester – are being published in JAMA Neurology. Several previous studies have suggested that urate elevation may reduce the risk of Parkinson disease or slow its progression.

"This study provided clear evidence that, in people with early Parkinson disease, inosine treatment can safely elevate urate levels in the blood and cerebrospinal fluid for months or years," says Michael Schwarzschild, MD, PhD, principal investigator of the study and an MGH neurologist. "We know that urate has neuroprotective properties in animal models, and an unusual convergence of human studies suggested its possible use as a disease-modifying strategy in Parkinson's; so the positive results of this trial are very encouraging."

Characterized by tremors, rigidity, difficulty walking and other symptoms, Parkinson disease is caused by the destruction of brain cells that produce the neurotransmitter dopamine. While current treatments can partially relieve symptoms, no therapy has been shown to alleviate the underlying loss of brain cells or the progression of the disorder. Studies by Schwarzschild's team and others have found that healthy people with naturally occurring blood levels of urate within the high normal range appear to have a reduced risk of developing Parkinson's and that the disease may progress more slowly in those with higher urate levels.

Primarily supported by a $5.6 million grant from the The Michael J. Fox Foundation for Parkinson's Research and conducted at 17 sites across the U.S., SURE-PD (Safety of URate Elevation in Parkinson's Disease) enrolled 75 recently diagnosed Parkinson disease patients with relatively low blood levels of urate (less than 6 mg/dL). Participants were randomized to three study groups – one receiving an inosine dosage designed to achieve mild elevation of blood urate (6 to 7 mg/dL), one receiving a dose designed to achieve moderate elevation (7 to 8 mg/dL) and a placebo group. Inosine is naturally converted by the body into urate as part of normal metabolism, whereas urate taken orally would be broken down in the digestive system.

Of the 75 participants only 1 did not complete the trial. During the study period, the incidence of serious adverse events was no higher among those receiving inosine than among the placebo group. Three participants receiving inosine did develop symptomatic kidney stones – a known consequence of high urate levels – but two of those were not clearly urate-related stones, and all were successfully treated. There was no increased incidence of gout or other potentially urate-related problems. After six months on the trial, 95 percent of participants reported no problems taking the drug, and while several discontinued treatment for varying periods of time during the study period, the investigators estimate that 90 percent would have tolerated the treatment if they had continued the full two years.

The tested dosages successfully increased blood and cerebrospinal fluid urate levels into the target ranges, with greater increases in the moderate-elevation group. One month after the study ended, urate levels for all participants had returned to their original levels. Additional data collected by the investigators provided preliminary effectiveness results that Schwarzschild describes as encouraging. "These results support advancing to a larger trial capable of addressing whether inosine might fill the critical unmet need for disease-modifying treatment. The information provided by this trial is helping us design a phase 3 trial, and with guidance from the FDA, we are preparing an application for additional funding from the National Institutes of Health."

A professor of Neurology at Harvard Medical School, Schwarzschild cautions Parkinson's patients and their caregivers against attempting inosine treatment at this time. "While there is considerable evidence to support this therapy's potential, inosine is still an unproven treatment for Parkinson disease. We know that excessively high urate can lead to kidney stones, gout and possibly other untoward effects, which is why attempts to elevate urate are best pursued in carefully designed clinical trials where the risks can be reduced and balanced against possible benefits."

INFORMATION:

Co-principal investigators of the SURE-PD trial are Alberto Ascherio, MD, DrPH, Harvard School of Public Health; and Karl Kieburtz, MD, MPH, University of Rochester. Eric Macklin, PhD, of the MGH Department of Medicine was the trial's lead biostatistician.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

END



ELSE PRESS RELEASES FROM THIS DATE:

Gene therapy method targets tumor blood vessels

2013-12-27
Gene therapy method targets tumor blood vessels Working in mice, researchers at Washington University School of Medicine in St. Louis report developing a gene delivery method long sought in the field of gene therapy: a deactivated virus ...

Children at lower risk for peanut, tree nut allergies if moms ate more nuts while pregnant

2013-12-27
Children at lower risk for peanut, tree nut allergies if moms ate more nuts while pregnant Children appear to be less at risk for developing peanut or tree nut (P/TN) allergies if their mothers are not allergic and ate more nuts during pregnancy, ...

Study examines inosine to increase urate levels in patients with Parkinson disease

2013-12-27
Study examines inosine to increase urate levels in patients with Parkinson disease The drug inosine appears to be a safe and effective way to raise blood and cerebrospinal fluid urate levels in patients with early Parkinson disease (PD), suggesting it may ...

Increase in consultations for Medicare patients before cataract surgery

2013-12-27
Increase in consultations for Medicare patients before cataract surgery Preoperative consultations before cataract surgery became more common for Medicare patients despite no clear guidelines about when to require such a service, hinting at unnecessary use of health ...

Mongooses synchronize births to escape despotic females

2013-12-27
Mongooses synchronize births to escape despotic females Some mammals may have evolved to synchronise births as a way of evading the threat of infanticide, according to a study led by the University of Exeter. To ensure groups remain productive, some ...

Breast cancer patients experience fewer side effects from anticancer drug when receiving acupuncture

2013-12-27
Breast cancer patients experience fewer side effects from anticancer drug when receiving acupuncture A new analysis has found that both real and sham acupuncture treatments may help alleviate side effects of drugs commonly used to treat breast cancer. Published early online in ...

Pregnant women need not avoid peanuts, evidence shows

2013-12-27
Pregnant women need not avoid peanuts, evidence shows Peanut and tree nut allergy incidence lower among children whose mothers ate them during pregnancy BOSTON (Dec. 23, 2013)—Women need not fear that eating peanuts during pregnancy could cause ...

Embargoed study: New quality, payment initiative positively impacts pediatric care

2013-12-27
Embargoed study: New quality, payment initiative positively impacts pediatric care Contracting model, based on global payment and pay-for-performance, improves quality of care for sickest pediatric patients BOSTON (Dec. 23, 2013)—Within two years ...

Preop testing for low-risk cataract surgery patients: Choosing wisely or low-value care? Penn Medicine

2013-12-27
Preop testing for low-risk cataract surgery patients: Choosing wisely or low-value care? Penn Medicine (PHILADELPHIA) – The elimination of extensive routine preoperative tests and consultations represents an area of ...

Getting excited helps with performance anxiety more than trying to calm down, study finds

2013-12-27
Getting excited helps with performance anxiety more than trying to calm down, study finds Simple statements about excitement could have big effects, research shows WASHINGTON – People who tell themselves to get excited rather than trying to relax ...

LAST 30 PRESS RELEASES:

Breast cancer risk in younger women may be influenced by hormone therapy

Strategies for staying smoke-free after rehab

Commentary questions the potential benefit of levothyroxine treatment of mild hypothyroidism during pregnancy

Study projects over 14 million preventable deaths by 2030 if USAID defunding continues

New study reveals 33% gap in transplant access for UK’s poorest children

Dysregulated epigenetic memory in early embryos offers new clues to the inheritance of polycystic ovary syndrome (PCOS)

IVF and IUI pregnancy rates remain stable across Europe, despite an increasing uptake of single embryo transfer

It takes a village: Chimpanzee babies do better when their moms have social connections

From lab to market: how renewable polymers could transform medicine

Striking increase in obesity observed among youth between 2011 and 2023

No evidence that medications trigger microscopic colitis in older adults

NYUAD researchers find link between brain growth and mental health disorders

Aging-related inflammation is not universal across human populations, new study finds

University of Oregon to create national children’s mental health center with $11 million federal grant

Rare achievement: UTA undergrad publishes research

Fact or fiction? The ADHD info dilemma

Genetic ancestry linked to risk of severe dengue

Genomes reveal the Norwegian lemming as one of the youngest mammal species

Early birds get the burn: Monash study finds early bedtimes associated with more physical activity

Groundbreaking analysis provides day-by-day insight into prehistoric plankton’s capacity for change

Southern Ocean saltier, hotter and losing ice fast as decades-long trend unexpectedly reverses

Human fishing reshaped Caribbean reef food webs, 7000-year old exposed fossilized reefs reveal

Killer whales, kind gestures: Orcas offer food to humans in the wild

Hurricane ecology research reveals critical vulnerabilities of coastal ecosystems

Montana State geologist’s Antarctic research focuses on accumulations of rare earth elements

Groundbreaking cancer therapy clinical trial with US Department of Energy’s accelerator-produced actinium-225 set to begin this summer

Tens of thousands of heart attacks and strokes could be avoided each year if cholesterol-lowering drugs were used according to guidelines

Leading cancer and metabolic disease expert Michael Karin joins Sanford Burnham Prebys

Low-intensity brain stimulation may restore neuron health in Alzheimer's disease

Four-day school week may not be best for students, review finds

[Press-News.org] Inosine treatment safely elevates urate levels in Parkinson's disease patients
Phase 2 trial supports further investigation of urate's ability to slow disease progression